ONDEMAND

CardioMet'24

Canada's Premiere Virtual Cardiovascular Symposium

Canada's Premiere Virtual Cardiovascular Symposium

CardioMet'24 was Canada's premiere, virtual cardiovascular symposium. Aimed at cardiovascular specialists, this multi-day virtual conference highlighted topics of major interest or controversy across six therapeutic themes. Featuring world-class faculty, interactivity, and cutting edge science, CardioMet'24 was unlike any other cardiovascular conference in Canada.

Recorded live on:

19th & 26th JANUARY 2024

Program Themes

19th JANUARY 2024

- Imaging
- Structural Heart
- CAD/ACS

26th JANUARY 2024

- Atrial Fibrillation
- Heart Failure
- Prevention

Watch now!

Opening Address

Robert M. Califf
MD
Commissioner,
Food and Drug Administration

Keynote Speakers

Ami Bhatt
MD, FACC
Chief Innovation Officer,
American College of Cardiology

Eugene Braunwald
MD, MACC
Harvard University

Learning Objectives:

- Discuss the latest advances in cardiovascular risk factor management and prevention.
- Explain new developments in the management of heart failure and atrial fibrillation.
- Explore new imaging techniques employed in the management of structural heart disease.

View OnDemand

https://www.ccrnmd.com/cardiomet--24

This program received an educational grant from:

Innovation Level – HLS Therapeutics
Impact Level – Amgen, Novartis
Benefactor Level – Anthos Therapeutics, AstraZeneca

AGENDA

Friday, **January 19th, 2024**

CardioMet'24
Canada's Premiere Virtual Cardiovascular Symposium

CCRN Canadian Collaborative Research Network

12:00 - 12:10	**Welcome and opening remarks**	**Milan Gupta**
OPENING ADDRESS		
12:10 - 12:30	ROLE OF FDA IN COMBATTING THE PUBLIC HEALTH THREAT OF CARDIOMETABOLIC DISEASE	**Robert M. Califf**
12:30 - 12:40	DISCUSSION	
KEYNOTE ADDRESS		
12:40 - 1:00	AI AND CARDIOLOGY: FRIEND OR FOE?	**Ami Bhatt**
1:00 - 1:10	DISCUSSION	
IMAGING	**Moderators: Margot Davis/Jacob Udell**	
1:15 - 1:35	ASSESSMENT OF CORONARY PLAQUE IN THE CATH LAB: BEYOND ANGIOGRAPHY	**Erick Schampaert**
1:35 - 1:55	CARDIAC CT ANGIOGRAPHY: STRENGTHS AND LIMITATIONS	**Jonathan Leipsic**
1:55 - 2:15	PRACTICAL APPLICATIONS OF CARDIAC MRI	**Kate Hanneman**
2:15 - 2:35	DISCUSSION	

Learning Objectives

- Describe the role of the FDA in helping to manage cardiometabolic disease
- Identify the current and future role of AI in cardiology
- Evaluate new and emerging strategies for coronary plaque assessment
- Describe the role and value of Cardiac CT angiography and cardiac MRI as a diagnostic tool

2:35 - 2:55	**REFRESHMENT BREAK**	
STRUCTURAL HEART	**Moderators: Margot Davis/Anique Ducharme**	
3:00 -3:20	CHALLENGES IN TAVR: BICUSPID VALVES AND ASYMPTOMATIC PATIENTS	**David Wood**
3:20 - 3:40	MITRAL TEER: SELECTING THE RIGHT PATIENT	**Anique Ducharme**
3:40 - 4:00	TRICUSPID REGURGITATION: INNOCENT BYSTANDER OR CULPRIT?	**Louis-Philippe David**
4:00 - 4:20	DISCUSSION	

Learning Objectives

- Explore the growing role of TAVR in bicuspid valves and asymptomatic patients
- Identify patients who can most benefit from Mitral TEER procedure
- Determine the association between tricuspid regurgitation and long-term outcomes

CAD/ACS	**Moderators: Milan Gupta/Jacob Udell**	
4:25 - 4:45	CULPRIT LESION OR COMPLETE REVASCULARIZATION FOR ACS?	**Shamir Mehta**
4:45 - 5:05	DAPT FOLLOWING ACS: DOES ONE SIZE FIT ALL?	**Marc Bonaca**
5:05 - 5:25	DOES PCI FOR STABLE CAD OFFER ANY BENEFITS?	**Rasha Al-Lamee**
5:25 - 5:45	SHOULD COLCHICINE BECOME STANDARD THERAPY FOR CAD?	**Paul Ridker**
5:45 - 6:10	DISCUSSION	

Learning Objectives

- Distinguish the appropriate revascularization strategy for ACS patients
- Describe the evolving role of DAPT following ACS
- Review the clinical benefits of PCI in stable angina
- Identify the role of colchicine and vascular inflammation as a target of therapy

6:10 - 6:15	**MEETING CLOSE**	**Milan Gupta**

Friday, **January 26th, 2024**

12:00 - 12:25	**Unaccredited Session**	
12:25 - 12:35	Welcome and opening remarks	**Milan Gupta**

ATRIAL FIBRILLATION

Moderators: Milan Gupta/Jacob Udell

12:40 - 12:55	ABLATION - WHO, WHEN AND HOW?	**Jason Andrade**
12:55 - 1:10	LEFT ATRIAL APPENDAGE CLOSURE - WHO, WHEN AND HOW?	**Jacqueline Saw**
1:10 - 1:25	ARE FACTOR XI/XIa INHIBITORS THE FUTURE OF STROKE PREVENTION?	**Christian Ruff**
1:25 - 1:40	WEARABLES AND AF DETECTION: HOW MUCH IS ENOUGH?	**Chris Cheung**
1:40 - 2:00	DISCUSSION	

Learning Objectives

- Determine the ideal patient and ablation type for AF
- Examine the role of LAAC for stroke prevention
- Explore the emerging role of Factor XI/XIa Inhibitors in stroke prevention
- Determine the minimum duration of AF required for stroke prevention strategies

KEYNOTE ADDRESS

2:05 - 2:30	HYPERTROPHIC CARDIOMYOPATHY: THE PAST, THE PRESENT, AND THE FUTURE	**Eugene Braunwald**
2:30 -2:40	DISCUSSION	
2:40 - 3:05	**REFRESHMENT BREAK**	

HEART FAILURE

Moderators: Margot Davis/Milan Gupta

3:10 - 3:25	HFpEF, HFmrEF, HFrEF: ONE DISEASE OR NOT?	**Biykem Bozkurt**
3:25 - 3:40	OPTIMIZING TREATMENT QUICKLY IN HFrEF: A PRACTICAL APPROACH	**Peter Liu**
3:40 - 3:55	DIAGNOSIS AND TREATMENT OF CARDIAC AMYLOIDOSIS	**Margot Davis**
3:55 - 4:10	DISCUSSION	

Learning Objectives

- Apply new treatment options in patients with hypertrophic cardiomyopathy
- Examine the similarities and differences between HFpEF, HFmrEF, HFrEF
- Apply best practices to rapidly optimize treatment for HFrEF patients
- Explain guideline centric diagnostic and new treatment strategies for Cardiac Amyloidosis

PREVENTION

Moderators: Milan Gupta/Jacob Udell

4:15 - 4:35	THE DISRUPTIVE SCIENCE OF LDL-LOWERING: FROM STATINS TO PCSK9 MANIPULATION	**Milan Gupta**
4:35 - 4:55	DECODING THE CARDIOVASCULAR BENEFITS OF ICOSAPENT ETHYL	**Deepak L. Bhatt**
4:55 - 5:15	IS Lp(a) THE NEXT FRONTIER?	**Marlys Koschinsky**
5:15 - 5:35	IS OBESITY MANAGEMENT THE NEXT FRONTIER?	**A. Michael Lincoff**
5:35 - 6:00	DISCUSSION	

Learning Objectives

- Summarize the revolution and future developments in the arena of LDL-Lowering
- Examine the role of triglycerides and icosapent ethyl in cardiovascular risk reduction
- Explore the potential of Lp(a) lowering for CV risk reduction
- Explain the advances in obesity management and future opportunities for risk reduction

6:00 - 6:05	**CLOSING COMMENTS**	**Milan Gupta**

CCRN Canadian Collaborative Research Network

Watch OnDemand
https://www.ccrnmd.com/webcasts

Watch Now!

For inquiries regarding this program, please contact info@ccrnmd.com.